• PROCEPT BioRobotics recently reported two milestones in its WATER IV prostate cancer program: completing enrollment in the 280-patient randomized trial comparing Aquablation to radical prostatectomy and securing FDA IDE approval for a second randomized study against active surveillance in up to 333 patients.
• These long-term, randomized trials could help clarify how Aquablation stacks up against both surgery and watchful waiting on cancer control and quality-of-life outcomes over a ten-year horizon.
• We’ll now examine how the completion of the pivotal WATER IV enrollment may influence PROCEPT BioRobotics’ broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can become a core urology platform across both BPH and prostate cancer, supporting sustained revenue growth despite continuing losses and reimbursement and competition pressures. The completion of WATER IV enrollment matters mainly as a clinical proof point rather than a near term financial driver, but it still feeds into the key catalyst of broader indication expansion, while the biggest near term risk remains execution on system utilization and cost control rather than trial timelines.

Among recent developments, the Q1 2026 beat and reaffirmed full year revenue guidance of US$390 million to US$410 million keeps the near term growth story intact, even as PROCEPT invests heavily in trials like WATER IV. For investors tracking catalysts, this combination of stronger than expected current system and handpiece demand with long duration cancer studies highlights the tension between today’s operating losses and the long run potential that more optimistic analysts are focused on.

Yet behind the excitement around Aquablation’s cancer trials, investors should be aware of the concentrated technology risk if...

PROCEPT BioRobotics’ narrative projects $608.2 million revenue and $77.8 million earnings by 2029.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 12% upside to its current price.

Exploring Other Perspectives

More bullish analysts were already assuming roughly 26 percent annual revenue growth to about US$624.2 million and a swing to US$43.1 million in earnings by 2029, so this new WATER IV progress could either reinforce that optimistic view or prompt you to reconsider how much single technology and reimbursement risk you are comfortable with.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.